Alzheimer’s dementia (AD) is the most common type of dementia.1 Patients living with AD have a lower quality of life due to deterioration in function, cognition, behaviour and mental health over time, as well as increased mortality.2 Pharmacological treatment for AD predominantly consists of cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and the N-methyl-d-aspartate receptor antagonist, memantine. This evidence concerns the gene BCHE and Alzheimer disease.